Inventiva S.A. (IVA) is a clinical-stage French biopharmaceutical company developing oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis, or MASH. Its lead asset, lanifibranor, is the only pan-PPAR agonist in late-stage development for the disease and is being tested in the 1,009-patient pivotal Phase 3 NATiV3 trial. The company's Nasdaq-listed ADSs closed Wednesday at $3.39 and last changed hands at $3.44, a gain of $0.05, or 1.47% — a modest advance in absolute terms, but one delivered through a far more dramatic intraday path. No verified catalyst was found for the session's price action.
No verified news or fundamental catalyst found to explain Thursday's trading. There was no new corporate release, no securities filing, no fresh analyst rating change and no MASH-specific regulatory development published before the move. The most recent company-specific items remain the third-quarter business update cadence and management's comments at a healthcare conference on November 9, when Inventiva repeated that NATiV3 topline results are expected in the fourth quarter of 2026 and indicated data should arrive within roughly eight weeks. That is a forward-looking scheduling statement, not a new event, and it does not account for a 1.47% daily change.
The most plausible assessment is that the session reflected speculative positioning and thin liquidity rather than information. The stock opened at $3.45, climbed to $3.675 within the first hour and a half of trading, then reversed almost entirely — a pattern consistent with a small number of large buy orders moving a lightly traded order book and then meeting supply. The move also follows a violent three-session sequence: shares fell 9.8% on Monday and another 3.0% on Tuesday before rebounding 5.3% on Wednesday on roughly 3.5 million shares. Pulling back to $3.44 after an 8% morning spike is consistent with short-term profit-taking inside a stock that habitually moves several percent a day, rather than a repricing on fundamentals.
Volume did not confirm the move. About 0.7 million shares had changed hands by midday, a pace well below the 2.28 million-share daily average and far below Wednesday's 3.5 million-share session, which itself came on the stock's rebound rather than a news event. Light participation alongside a large intraday reversal argues against institutional accumulation.
The advance was not part of a broad MASH rally. Madrigal Pharmaceuticals (MDGL), the only approved MASH therapy and the sector's bellwether, fell 5.7% on Wednesday as litigation-related investigations persisted, and small-cap biotechnology generally traded mixed. Inventiva therefore diverged from its closest peer rather than following sector momentum, reinforcing the read that the move was idiosyncratic and flow-driven.
Technically, the rally stalled at $3.675 — still below the 50-day moving average near $3.56 on a closing basis and well below the 200-day average near $4.71. The stock remains deep inside a 52-week range of $2.82 to $7.29 and about 53% below its January high, so the bounce did nothing to alter the broader downtrend or reclaim meaningful resistance.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Inventiva scores 5 out of 100.
Both components are weak. No verified news was found, and the fundamental information available — a Phase 3 readout still weeks away — is unchanged in substance. The price move was also unremarkable by the stock's own standards: at 1.47%, it was roughly half the 3.2% average absolute daily change recorded over the last 70 sessions, and 42 of the prior 69 sessions produced a move at least this large. A routine swing in a highly volatile name with no new information combines into a very low score.
Everything now hinges on the NATiV3 topline. The trial completed its final 72-week patient visit in early September, and management has guided to data in the fourth quarter of 2026 — an event that will determine whether lanifibranor supports a new drug application filing in the first half of 2027. Investors will focus on the composite endpoint of MASH resolution with fibrosis improvement, the magnitude of benefit at the 1,200 mg dose, and tolerability, particularly the fluid retention and weight-gain profile that has dominated analyst questions all year.
Financially, the company reported €233.9 million in combined cash, equivalents and short-term deposits at mid-year, with runway extending into the second quarter of 2027 and potentially into early 2028 if warrant and debt tranches convert on positive data. A quarterly revenue and cash-position update is expected in the near term, with full-year 2026 results due in the first quarter of 2027. The consensus rating remains strongly positive, but the principal risks are binary: a miss on the primary endpoint, a narrow win that underwhelms on fibrosis, or any trial-related delay. Until the data arrives, expect continued double-digit percentage swings on minimal news.
Tickeron's Trending AI Robots page curates the strongest performing automated strategies under current market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, and only those posting the best results right now earn a place in this section. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the lineup shifts as market conditions change. Reviewing the current leaders is a practical way to see how adaptive, rules-based systems are positioned heading into the next session.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 40 cases where IVA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 80%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for IVA crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +7.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVA advanced for three days, in 175 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 121 of 156 cases where IVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The 10-day RSI Indicator for IVA moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 23 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IVA as a result. In 85 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for IVA turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 39 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
IVA moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. IVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.215) is normal, around the industry mean (3.596). P/E Ratio (-7.170) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (136.986) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases
Industry Biotechnology